Besarab A, Medina F, Musial E, Picarello N, Michael H
Department of Medicine (Division of Nephrology), College of Medicine of Thomas Jefferson University, Philadelphia, Pennsylvania.
ASAIO Trans. 1990 Jul-Sep;36(3):M749-53.
The incidence of vascular access clotting was evaluated over 5.25 years. The first 32 months served as a control period. During the second period of 31 months, recombinant human erythropoietin (epoetin) was used for an average duration of 13 months (range, 2-32 months) in 79 patients. The overall incidence of vascular access clotting decreased from a monthly rate of 0.06 to 0.03 events per patient-month over the 5 year period. Distribution of the number of events per patient did not differ between the two periods, with 55% to 60% of patients having no clotting episode. Patients with recurrent clotting (two or more events) accounted for 68% of episodes. During the second period, there were no differences in the incidence of vascular access clotting in epoetin treated patients vs untreated patients (0.38 events per patient-year vs. 0.46 events per patient-year, both slightly lower than in period 1 [0.52 events per patient-year]). It is concluded that epoetin does not increase vascular access clotting.
在5.25年的时间里评估了血管通路凝血的发生率。最初的32个月作为对照期。在随后的31个月期间，79例患者使用重组人促红细胞生成素（促红素）的平均时长为13个月（范围为2至32个月）。在这5年期间，血管通路凝血的总体发生率从每月每位患者0.06次事件降至0.03次事件。两个时期每位患者的事件数分布无差异，55%至60%的患者无凝血发作。有复发性凝血（两次或更多次事件）的患者占发作次数的68%。在第二个时期，促红素治疗患者与未治疗患者的血管通路凝血发生率无差异（分别为每位患者每年0.38次事件和0.46次事件，均略低于第一时期[每位患者每年0.52次事件]）。得出的结论是，促红素不会增加血管通路凝血。
